lineage,string,ID
B.1.1.529,"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron B.1.1.529 (or Nextstrain 21M) variant, first detected in November 2021, includes several sub-lineages, including BA.1 (B.1.1.529.1 or Nextstrain clade 21K), BA.2 (B.1.1.529.2 or Nextstrain clade 21L), and BA.3 (B.1.1.529.3 or Nextstrain clade 21M) (Figure 1
; Data S1; Hadfield et al., 2018; Sagulenko et al., 2018).",PMC9174147
B.1.1.7,"Notably, the BA.2 S protein NTD lacks the H69-V70 deletion (ΔH69-V70) that is present in BA.1, as well as in the Alpha (B.1.1.7) and a mink-associated (ΔFV) variant (Gobeil et al., 2021b; Meng et al., 2021).",PMC9174147
B.1,"Further mutational studies and careful evaluation of point mutants will be required to clarify the contribution of each substitution on the observed differences in the BA.2 S architecture..


REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesACE2(Henderson et al., 2020)N/ACR3022(Henderson et al., 2020)N/A2G12(Williams et al., 2021)N/AGoat anti-rabbit-HRPAbcamab97080Goat anti-human-HRPJackson ImmunoResearch Laboratories109-035-098Mouse anti-monkey IgG HRPSouthern BiotechCat #:4700-05; RRID:AB_2796069DH1050.1(Li et al., 2021)N/ADH1052(Li et al., 2021)N/AS309(Pinto et al., 2020)N/ADH1041(Li et al., 2021)N/ADH1042(Li et al., 2021)N/ADH1047(Li et al., 2021)N/AS2X259(Totorici et al., 2021)N/ADH1044(Li et al., 2021)N/ADH1193(Li et al., 2021)N/ADH1058(Li et al., 2021)N/ABacterial and virus strainsSpike-pseudotyped virus D614G (B.1)David Montefiori & Xiaoying Shen, DukeSpike-pseudotyped virus Omicron (B.1.1.529.1)David Montefiori & Xiaoying Shen, DukeSpike-pseudotyped virus Omicron (B.1.1.529.2)David Montefiori & Xiaoying Shen, DukeSpike-pseudotyped virus Omicron (B.1.1.529.3)David Montefiori & Xiaoying Shen, DukeChemicals, peptides, and recombinant proteinsFreeStyle 293 Expression MediumGIBCO12,338,018Expi293 Expression MediumGIBCOA1435101ExpiFectamine 293 Transfection KitGIBCOA14524Hyclone SFM4HEK293CytivaSH30521.02Opti-MEM IGIBCO31,985-070Turbo293Speed BioSystemsPXX100210x Buffer EIBA2-100010x Buffer RIBA2-100210x Buffer WIBA2-1003Strep-Tactin resinIBA2-12018% GlutaraldehydeElectron Microscopy Sciences16,019300mesh Cu carbon coatedElectron Microscopy SciencesCF300-CuUranyl formateElectron Microscopy Sciences22,450S-888Quantifoil R 1.2/1.3 300 meshElectron Microscopy SciencesQ350CR-14StreptavidinThermo Fisher ScientificS-888Streptavidin-HRPThermo ScientificRef #21132D-mannoseSigmaCAS #:3458-28-4Tween 20SigmaP7949Phosphate Buffered Saline (25x) pH 7.6Cat No:PBS-20000Sodium BicarbonateSigmaS6297Sodium AzideSigmaS8032Hydrochloric AcidFischer ScientificA142-212Whey ProteinBipro USAUnflavored WheyGoat SerumInvitrogen16,210-072SureBlue Reserve TMBKPL53-00-03BSASigmaA3059HBS-EP + buffer 10xCytivaBR100669Critical commercial assaysSuperose 6 Increase 10/300 GLCytiva29,091,596NuPage 4-12%InvitrogenNP0321TMB substrateSera Care Life Sciences5120-0083Luciferase Cell Culture Lysis 5x ReagentPromegaCat# E1531Bright-Glo Luciferase Assay SystemPromegaCat# #2650Series S CM5 Sensor chipCytiva29,104,988Series S SA sensor chipCytivaBR100398Human Antibody Capture kitCytivaBR100839Deposited dataSARS-CoV-2 Omicron-BA.2 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-Omicron-BA.2)This studyPDB 7UB0; EMDB- 26,433SARS-CoV-2 Omicron-BA.2 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-Omicron-BA.2)This studyPDB 7UB5; EMD- 26435SARS-CoV-2 Omicron-BA.2 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-Omicron-BA.2)This studyPDB 7UB6; EMD- 26436SARS-CoV-2 Omicron-BA.2 1-RBD-up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-Omicron-BA.2)This studyEMD- 26644SARS-CoV-2 Omicron-BA.2 1-RBD-up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-Omicron-BA.2)This studyEMD- 26647SARS-CoV-2 Omicron-BA.2 1.5-RBD up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-Omicron-BA.2)This studyEMD-26643Experimental models: Cell linesFreestyle 293-F cellsGIBCOR79007Expi293F cellsGIBCOA14527293T/ACE2 cellsDrs.",PMC9174147
B.1.1.7,"This strain clade 201/501Y.V1, Pango lineage B.1.1.7, and GISAID clade are all recognized Alpha variant by various scientific names.",PMC9088647
B.1.351,"26
 There are three mutations of significant importance in the spike area of the lineage, B.1.351 genome, K417N, E484K, N501Y, and a further five spike mutations, L18F, D80A, D215G, R246I, A701V, that have so far raised little concern.",PMC9088647
P.1,"56
 Safety and immunogenicity study of a SARS‐CoV‐2 variant vaccine (mRNA‐1273.351) is currently ongoing sponsored by The National Institute of Allergy and Infectious Diseases (NIAID) (NCT04785144)..

Lineage P.1, frequently referred to as the gamma variant, is a cause of COVID‐19.",PMC9088647
P.2,Gamma variant is particularly found from the other Brazilian zeta variant (Lineage P.2).,PMC9088647
B.1.429,"These resembling variants, B.1.427 and B.1.429 (epsilon variant), were initially identified in California (USA).",PMC9088647
B.1.427,"These resembling variants, B.1.427 and B.1.429 (epsilon variant), were initially identified in California (USA).",PMC9088647
B.1.617,"B.1.617.2 (Delta variant) is a variant of lineage B.1.617 of SARS‐CoV‐2, which is the reason for India's second wave in this pandemic of COVID‐19.",PMC9088647
B.1.617.1,"83
 The B.1.617.1 strain is 6.8‐fold more resistant to neutralization by sera from COVID‐19 convalescent and Moderna and Pfizer vaccinated patients, according to a live virus experiment.",PMC9088647
C.1.2,"92
 Researchers discovered that this new C.1.2 variant is evolving and mutating at a faster pace inside its genome than other VOC or VOI along with the Delta variant.",PMC9088647
B.1.1.529,"K417N, N440K, G446S, S477N, T478K, E484A, Q493K, G496S, Q498R, N501Y, Y505H, and P681H are the most common spike protein mutations found in omicron variant.”
94
 According to preliminary laboratory findings, three doses of the Pfizer‐BioNTech COVID‐19 vaccine neutralize the Omicron variation (B.1.1.529 lineage), but two doses had much lower neutralization titers.",PMC9088647
B.1.617,"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant of concern (VOC) (Phylogenetic Assignment of Named Global Outbreak Lineages (Pangolin) designation B.1.617) sub-lineage AY.4.2 recently accounted for an increased proportion of coronavirus disease (COVID-19) cases caused by the Delta variant in the United Kingdom (UK), increasing from 3.8% to 20.3% in the weeks of 19 September 2021 and 15 November 2021, respectively [1,2].",PMC8662802
B.1.617.2,The titres for AY.4.2 did not differ significantly from those measured for the parental Delta lineage B.1.617.2 (median titre: 87 vs 118; p > 0.050) or Delta sub-lineage AY.4 (median titre: 87 vs 118; p > 0.050).,PMC8662802
P.1,"Virus neutralisation titres for other VOC, Alpha (Pango lineage designation B.1.1.7), Beta (Pango lineage designation B.1.351) and Gamma (Pango lineage designation P.1) were available for 24 of the 30 serum samples (Figure 3).",PMC8662802
B.1.351,"Virus neutralisation titres for other VOC, Alpha (Pango lineage designation B.1.1.7), Beta (Pango lineage designation B.1.351) and Gamma (Pango lineage designation P.1) were available for 24 of the 30 serum samples (Figure 3).",PMC8662802
B.1.1.7,"Virus neutralisation titres for other VOC, Alpha (Pango lineage designation B.1.1.7), Beta (Pango lineage designation B.1.351) and Gamma (Pango lineage designation P.1) were available for 24 of the 30 serum samples (Figure 3).",PMC8662802
B.1.1.529,"In addition, similar studies are urgently needed for the recently identified Omicron VOC (Pango lineage designation B.1.1.529) and its sub-lineages [18], which bear different spike mutations..

We would like to thank Birgit Knudsen, Louise Borup, and Dennis Jelsbak Schmidt for technical assistance.",PMC8662802
B.1.617.2,"However, the titers for AY.4.2 did not differ significantly from those measured for the parental Delta lineage B.1.617.2 (median titer: 87 vs. 118; P > 0.050) or Delta sublineage AY.4 (median titer: 87 vs. 118; P > 0.050).",PPR417362
P.1,"Four SARS-CoV-2 variants of concern including B.1.1.7, B.1.351, B.1.617.2, and P.1, and two variants of interest including C.37 and B.1.621 have been reported to have potential immune escape, and one or more mutations endow them with worrisome epidemiologic, immunologic, or pathogenic characteristics.",PMC8602852
B.1.617.2,"Four SARS-CoV-2 variants of concern including B.1.1.7, B.1.351, B.1.617.2, and P.1, and two variants of interest including C.37 and B.1.621 have been reported to have potential immune escape, and one or more mutations endow them with worrisome epidemiologic, immunologic, or pathogenic characteristics.",PMC8602852
B.1.621,"Four SARS-CoV-2 variants of concern including B.1.1.7, B.1.351, B.1.617.2, and P.1, and two variants of interest including C.37 and B.1.621 have been reported to have potential immune escape, and one or more mutations endow them with worrisome epidemiologic, immunologic, or pathogenic characteristics.",PMC8602852
B.1.351,"Four SARS-CoV-2 variants of concern including B.1.1.7, B.1.351, B.1.617.2, and P.1, and two variants of interest including C.37 and B.1.621 have been reported to have potential immune escape, and one or more mutations endow them with worrisome epidemiologic, immunologic, or pathogenic characteristics.",PMC8602852
C.37,"Four SARS-CoV-2 variants of concern including B.1.1.7, B.1.351, B.1.617.2, and P.1, and two variants of interest including C.37 and B.1.621 have been reported to have potential immune escape, and one or more mutations endow them with worrisome epidemiologic, immunologic, or pathogenic characteristics.",PMC8602852
B.1.1.7,"Four SARS-CoV-2 variants of concern including B.1.1.7, B.1.351, B.1.617.2, and P.1, and two variants of interest including C.37 and B.1.621 have been reported to have potential immune escape, and one or more mutations endow them with worrisome epidemiologic, immunologic, or pathogenic characteristics.",PMC8602852
B.1.1.318,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
R.1,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
C.36.3,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
B.1.427,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
B.1.619,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
B.1.1.519,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
B.1.526,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
B.1.466.2,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
C.1.2,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
B.1.525,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
B.1.214.2,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
B.1.617.1,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
B.1.620,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
B.1.1.523,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/].",PMC8602852
P.3,"Some former VOIs but no longer designated as VUMs include P.2 (first detected in Brazil) and P.3 (first detected in the Philippines) (
Supplementary Figures 1
, 
2
) [Variants: distribution of cases data, 20 May 2021-GOV.UK (www.gov.uk)]..",PMC8602852
P.2,"Some former VOIs but no longer designated as VUMs include P.2 (first detected in Brazil) and P.3 (first detected in the Philippines) (
Supplementary Figures 1
, 
2
) [Variants: distribution of cases data, 20 May 2021-GOV.UK (www.gov.uk)]..",PMC8602852
B.1.1.28,"P.3 as well as P.1 belong to B.1.1.28 lineage (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/)..

With increased infectivity and virulence, a new variant with an L452R mutation in S protein appeared in California in March 2020, which was named B.1.427/429.",PMC8602852
B.1.617,"At the same time, B.1.525 was resistant to neutralization of convalescent serum, vaccine-elicited serum, and monoclonal antibodies (44)..

As of September 26, 2021, India’s confirmed cases in has reached 33,652,745, becoming the country with the second largest cumulative number of confirmed cases in the world, which was propelled by variant B.1.617 [https://coronavirus.jhu.edu/map.html].",PMC8602852
B.1.617.3,"With the spread of the local epidemic in India, B.1.617.1, B.1.617.2, and B.1.617.3 strains emerged successively.",PMC8602852
B.1.1.7,Epidemiological data demonstrate that SARS-CoV-2 variants of concern (VOC) B.1.1.7 and B.1.617.2 are more transmissible and infections are associated with a higher mortality than non-VOC virus infections.,PPR416637
B.1.617.2,Epidemiological data demonstrate that SARS-CoV-2 variants of concern (VOC) B.1.1.7 and B.1.617.2 are more transmissible and infections are associated with a higher mortality than non-VOC virus infections.,PPR416637
B.1,"B.1.1.7 virus isolates displayed inferior or equivalent spread in most cell lines and primary cells compared to an ancestral B.1 SARS-CoV-2, and were outcompeted by the latter.",PPR416637
B.1.351,"In accordance with reports by others (Bates et al., 2021; Supasa et al., 2021; Widera et al., 2021), B.1 infection- and vaccination-induced antibodies efficiently neutralized both B.1 and B.1.1.7 in a plaque reduction neutralization test, whereas such antibodies failed to effectively neutralize B.1.351 (Fig.",PPR416637
P.2,"Briefly, cells were expanded using the conditionally reprogrammed cell (CRC) culture method, then p.2 or p.3 cells were seeded on porous Transwell or Snapwell 1.1 cm2 supports (Corning) in UNC-ALI medium and differentiated at air-liquid interface for at least three weeks prior to infection.",PPR416637
P.3,"Briefly, cells were expanded using the conditionally reprogrammed cell (CRC) culture method, then p.2 or p.3 cells were seeded on porous Transwell or Snapwell 1.1 cm2 supports (Corning) in UNC-ALI medium and differentiated at air-liquid interface for at least three weeks prior to infection.",PPR416637
B.1.617.2,Viral sequencing revealed an infection cluster of 6 vaccinated patients infected with the delta (B.1.617.2) SARS-CoV-2 variant.,PMC8483940
P.1,"The online version contains supplementary material available at 10.1186/s12916-021-02103-4..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably alpha variant (B.1.1.7 UK), beta (B.1.351 S. Africa), gamma (P.1 Brazil), epsilon (B.1.429 California), iota (B.1.526 New York), and now, delta and kappa (B.1.617.2 and B.1.617.1 India).",PMC8483940
B.1.526,"The online version contains supplementary material available at 10.1186/s12916-021-02103-4..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably alpha variant (B.1.1.7 UK), beta (B.1.351 S. Africa), gamma (P.1 Brazil), epsilon (B.1.429 California), iota (B.1.526 New York), and now, delta and kappa (B.1.617.2 and B.1.617.1 India).",PMC8483940
B.1.429,"The online version contains supplementary material available at 10.1186/s12916-021-02103-4..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably alpha variant (B.1.1.7 UK), beta (B.1.351 S. Africa), gamma (P.1 Brazil), epsilon (B.1.429 California), iota (B.1.526 New York), and now, delta and kappa (B.1.617.2 and B.1.617.1 India).",PMC8483940
B.1.351,"The online version contains supplementary material available at 10.1186/s12916-021-02103-4..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably alpha variant (B.1.1.7 UK), beta (B.1.351 S. Africa), gamma (P.1 Brazil), epsilon (B.1.429 California), iota (B.1.526 New York), and now, delta and kappa (B.1.617.2 and B.1.617.1 India).",PMC8483940
B.1.617.1,"The online version contains supplementary material available at 10.1186/s12916-021-02103-4..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably alpha variant (B.1.1.7 UK), beta (B.1.351 S. Africa), gamma (P.1 Brazil), epsilon (B.1.429 California), iota (B.1.526 New York), and now, delta and kappa (B.1.617.2 and B.1.617.1 India).",PMC8483940
B.1.1.7,"The online version contains supplementary material available at 10.1186/s12916-021-02103-4..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably alpha variant (B.1.1.7 UK), beta (B.1.351 S. Africa), gamma (P.1 Brazil), epsilon (B.1.429 California), iota (B.1.526 New York), and now, delta and kappa (B.1.617.2 and B.1.617.1 India).",PMC8483940
P.1,"None of the patients had a history of failed vaccination..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably Alpha variant (B.1.1.7 UK), Beta (B.1.351 S. Africa), Gamma (P.1 Brazil), Epsilon (B.1.429 California), Iota (B.1.526 New York) and now, Delta and Kappa (B.1.617.2 and B.1.617.1 India).",PPR365548
B.1.617.2,"None of the patients had a history of failed vaccination..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably Alpha variant (B.1.1.7 UK), Beta (B.1.351 S. Africa), Gamma (P.1 Brazil), Epsilon (B.1.429 California), Iota (B.1.526 New York) and now, Delta and Kappa (B.1.617.2 and B.1.617.1 India).",PPR365548
B.1.526,"None of the patients had a history of failed vaccination..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably Alpha variant (B.1.1.7 UK), Beta (B.1.351 S. Africa), Gamma (P.1 Brazil), Epsilon (B.1.429 California), Iota (B.1.526 New York) and now, Delta and Kappa (B.1.617.2 and B.1.617.1 India).",PPR365548
B.1.429,"None of the patients had a history of failed vaccination..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably Alpha variant (B.1.1.7 UK), Beta (B.1.351 S. Africa), Gamma (P.1 Brazil), Epsilon (B.1.429 California), Iota (B.1.526 New York) and now, Delta and Kappa (B.1.617.2 and B.1.617.1 India).",PPR365548
B.1.351,"None of the patients had a history of failed vaccination..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably Alpha variant (B.1.1.7 UK), Beta (B.1.351 S. Africa), Gamma (P.1 Brazil), Epsilon (B.1.429 California), Iota (B.1.526 New York) and now, Delta and Kappa (B.1.617.2 and B.1.617.1 India).",PPR365548
B.1.617.1,"None of the patients had a history of failed vaccination..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably Alpha variant (B.1.1.7 UK), Beta (B.1.351 S. Africa), Gamma (P.1 Brazil), Epsilon (B.1.429 California), Iota (B.1.526 New York) and now, Delta and Kappa (B.1.617.2 and B.1.617.1 India).",PPR365548
B.1.1.7,"None of the patients had a history of failed vaccination..

High numbers of global SARS-CoV-2 infections have led to the emergence of variants, notably Alpha variant (B.1.1.7 UK), Beta (B.1.351 S. Africa), Gamma (P.1 Brazil), Epsilon (B.1.429 California), Iota (B.1.526 New York) and now, Delta and Kappa (B.1.617.2 and B.1.617.1 India).",PPR365548
B.1.617,The B.1.617 lineage is now widely circulating in over 50 countries based on viral sequence data and is classified as a variant of concern by the CDC.,PPR365548
